Showing 3421-3430 of 5621 results for "".
- EyePoint Completes Enrollment in Phase 3 LUGANO Trial of Duravyu for Treatment of Wet AMDhttps://modernod.com/news/eyepoint-completes-enrollment-in-phase-3-lugano-trial-of-duravyu-for-treatment-of-wet-amd/2482820/EyePoint Pharmaceuticals announced it has enrolled and randomized over 400 patients in the phase 3 LUGANO pivotal trial of Duravyu for the treatment of wet age-related macular degeneration (AMD). Enrollment took 7 months. LUGANO is the first of two pivotal noninferiority trial
- Eylea 8 mg Approved in China for Wet AMDhttps://modernod.com/news/eylea-8-mg-approved-in-china-for-wet-amd/2482817/The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has approved Eylea 8 mg (aflibercept 8 mg) for the treatment of wet age-related macular degeneration (AMD) in China. The approval is based on positive results from the phase 3 PULSAR trial a
- FDA Approves Genentech’s Susvimo for Diabetic Retinopathyhttps://modernod.com/news/fda-approves-genentechs-susvimo-for-diabetic-retinopathy/2482815/Genentech has received FDA approval for Susvimo (ranibizumab injection) 100 mg/mL for the treatment of diabetic retinopathy (DR). The approval makes Susvimo the first and only FDA-approved continuous delivery treatment shown to maintain vision in people with DR with one refill ever
- Bausch + Lomb Launches Lumify Preservative Free Redness Reliever Eye Drops in the UShttps://modernod.com/news/bausch-lomb-launches-lumify-preservative-free-redness-reliever-eye-drops-in-the-united-states/2482814/Bausch + Lomb announced the US launch of Lumify Preservative Free redness reliever eye drops, which the company describes as the first and only preservative-free over-the-counter (OTC) eye drops with low-dose brimonidine tartrate 0.025% that relieve redness of the eye due to m
- Allotex Files IDE with FDA for Collagen-Based Corneal Implanthttps://modernod.com/news/allotex-files-ide-with-fda-for-collagen-based-corneal-implant/2482813/Allotex announced the submission of its investigational device exemption (IDE) to the FDA, marking a step toward US clinical trials of the company’s human collagen-based corneal implant, Allo-1. Allo-1 offers a novel approach to near vision enhancement through biolo
- Grifols Receives FDA Clearance to Initiate Phase 2 Trial of Immunoglobulin Drops for Dry Eye Diseasehttps://modernod.com/news/grifols-receives-fda-clearance-of-ind-application-for-phase-2-trial-of-immunoglobulin-drops-for-dry-eye-disease/2482812/Grifols, a producer of plasma-derived medicines, announced that the FDA has cleared the company’s investigational new drug (IND) application to initiate a phase 2 trial evaluating its immunoglobulin (IG) drops–GRF312 ophthalmic solution–fo
- FDA Grants Atia Vision Approval to Begin US Clinical Trial of OmniVu Lens System in Patients with Cataractshttps://modernod.com/news/fda-grants-atia-vision-approval-to-begin-us-clinical-trial-of-omnivu-lens-system-in-patients-with-cataracts/2482811/Atia Vision has received Investigational Device Exemption (IDE) approval from the FDA to begin a traditional feasibility clinical study of its OmniVu Lens System. This novel IOL is designed to restore dynamic range of vision following catar
- Atsena Therapeutics Announces Positive Clinical Data for Gene Therapy to Treat X-linked Retinoschisis (XLRS)https://modernod.com/news/atsena-therapeutics-announces-positive-clinical-data-for-gene-therapy-to-treat-x-linked-retinoschisis-xlrs/2482808/Atsena Therapeutics announced interim data from Part A of its phase 1/2 LIGHTHOUSE clinical trial evaluating ATSN-201 for the treatment of X-linked retinoschisis (XLRS). The study demonstrated a favorable safety profile and compelling signs of efficacy in adul
- NIH Study: Experimental Drug May Help Treat Condition May Help Treat Diabetic Retinopathyhttps://modernod.com/news/nih-study-experimental-drug-may-help-treat-condition-may-help-treat-diabetic-retinopathy/2482805/A new National Institutes of Health (NIH)-funded study led by scientists at the Wilmer Eye Institute, Johns Hopkins Medicine researchers determined that low blood sugar, or hypoglycemia, may promote a breakdown of the blood-retinal barrier, an important boundary that regulates the flow of nu
- New World Medical Introduces Next-Generation Streamline Surgical Systemhttps://modernod.com/news/new-world-medical-introduces-next-generation-streamline-surgical-system-1/2482803/New World Medical has announced the launch of its enhanced Streamline Surgical System, which features a transparent tip designed to provide surgeons with improved visualization of key anatomical structures throughout the procedure. This latest advancement builds upon the original Streamline